Pace of BMS cancer trial leaves investors wary

Forget that Bristol-Myers Squibb ($BMY) beat analyst expectations for both profits and revenue Friday. Shareholders were focused on nivolumab, a cancer immunotherapy currently in development. So when BMS said it would continue its mid-stage instead of diving into a late-stage program testing it with melanoma hit Yervoy, investors feared it could mean problems with the combo--and sent shares down nearly 6%. More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.